Search results
Results From The WOW.Com Content Network
Shares of the San Francisco-based Cytokinetics surged over 80% to touch a more than a 19-year high of $83.82, on track to add as much as $3.74 bi Cytokinetics heart drug succeeds in closely ...
Shares of Cytokinetics with a market capitalization of over $9 billion, as of Friday's closing price, have more than tripled in value since Oct. 31, when reports of the company attracting takeover ...
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
A Cytokinetics spokesperson said the company does not comment on M&A speculation. The company is evaluating its experimental heart disease drug, aficamten, as a potential treatment for ...
Omecamtiv mecarbil. Omecamtiv mecarbil ( INN [1] ), previously referred to as CK-1827452, is a cardiac-specific myosin activator. It is an experimental drug being studied for a potential role in the treatment of left ventricular systolic heart failure. [2] Systolic heart failure involves a loss of effective actin -myosin cross bridges in the ...
Cytokinetics: CALX was moved from the S&P 400 as it was more representative of the small cap market space. CYTK was moved to the S&P 400 as it was more representative of the mid-cap market space. March 18, 2024: MPW: Medical Properties Trust: AIT: Applied Industrial Technologies
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Novartis may attempt to pursue a deal for Cytokinetics in the future or a different suitor may acquire the company, the person said. On Monday, Reuters reported that Novartis is in the lead to ...